Subtopic Deep Dive
Vaccine Development against Pathogenic Escherichia coli
Research Guide
What is Vaccine Development against Pathogenic Escherichia coli?
Vaccine development against pathogenic Escherichia coli targets subunit vaccines against fimbriae, flagella, and autotransporters to protect against diarrheagenic and extraintestinal E. coli pathotypes in preclinical animal models.
Research focuses on immunogenicity testing and adjuvant strategies due to the absence of approved vaccines for major E. coli pathotypes. Studies emphasize virulence factors in urinary tract infections (Flores-Mireles et al., 2015, 3932 citations) and extraintestinal pathogenic E. coli (Sarowska et al., 2019, 674 citations). Over 10 key papers document epidemiology and pathogen mechanisms.
Why It Matters
Pathogenic E. coli causes millions of urinary tract infections annually (Flores-Mireles et al., 2015) and significant diarrhea morbidity (Rahim et al., 2018; Guerrant et al., 2001). No licensed vaccines exist for extraintestinal or diarrheagenic strains, creating opportunities to reduce antibiotic reliance (Terlizzi et al., 2017). Effective vaccines could lower global disease burden from enteropathogenic and enterohaemorrhagic E. coli (Frankel et al., 1998).
Key Research Challenges
Antigenic Variability
Pathogenic E. coli strains show high genomic diversity, complicating broad vaccine coverage (Touchon et al., 2009, 1173 citations). Fimbriae and flagella antigens vary across pathotypes. Preclinical models struggle to predict human efficacy.
Immunogenicity in Models
Subunit vaccines against autotransporters elicit weak responses without adjuvants (Terlizzi et al., 2017). Animal challenge studies show inconsistent protection against extraintestinal infections (Sarowska et al., 2019). Translating to human trials remains unproven.
Pathotype Diversity
Diarrheagenic and extraintestinal E. coli require distinct targets (Frankel et al., 1998; Flores-Mireles et al., 2015). Virulence factors differ by source and host. No universal vaccine formulation exists.
Essential Papers
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
Ana L. Flores‐Mireles, Jennifer N. Walker, Michael G. Caparon et al. · 2015 · Nature Reviews Microbiology · 3.9K citations
Organised Genome Dynamics in the Escherichia coli Species Results in Highly Diverse Adaptive Paths
Marie Touchon, Claire Hoede, Olivier Tenaillon et al. · 2009 · PLoS Genetics · 1.2K citations
The Escherichia coli species represents one of the best-studied model organisms, but also encompasses a variety of commensal and pathogenic strains that diversify by high rates of genetic change. W...
Practice Guidelines for the Management of Infectious Diarrhea
Richard L. Guerrant, Thomas Van Gilder, Theodore S. Steiner et al. · 2001 · Clinical Infectious Diseases · 1.1K citations
The widening array of recognized enteric pathogens and the increasing demand for cost-containment sharpen the need for careful clinical and public health guidelines based on the best evidence curre...
Unravelling the biology of macrophage infection by gene expression profiling of intracellular <i>Salmonella enterica</i>
Sofia Eriksson, Sacha Lucchini, Arthur R. Thompson et al. · 2002 · Molecular Microbiology · 847 citations
Summary For intracellular pathogens such as Salmonellae , Mycobacteriae and Brucellae , infection requires adaptation to the intracellular environment of the phagocytic cell . The transition from e...
Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement
Marcello Chieppa, María Rescigno, Alex Y. Huang et al. · 2006 · The Journal of Experimental Medicine · 691 citations
Cells lining the gastrointestinal tract serve as both a barrier to and a pathway for infectious agent entry. Dendritic cells (DCs) present in the lamina propria under the columnar villus epithelium...
Virulence factors, prevalence and potential transmission of extraintestinal pathogenic Escherichia coli isolated from different sources: recent reports
Jolanta Sarowska, Bożena Futoma-Kołoch, Agnieszka Jama−Kmiecik et al. · 2019 · Gut Pathogens · 674 citations
Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016
Fakher Rahim, Christopher Troeger, Brigette F. Blacker et al. · 2018 · The Lancet Infectious Diseases · 667 citations
Reading Guide
Foundational Papers
Start with Flores-Mireles et al. (2015, 3932 citations) for UPEC epidemiology and mechanisms; Touchon et al. (2009, 1173 citations) for genomic diversity; Frankel et al. (1998) for diarrheagenic pathotypes.
Recent Advances
Sarowska et al. (2019, 674 citations) on extraintestinal virulence prevalence; Terlizzi et al. (2017, 664 citations) on UPEC vaccine strategies; Rahim et al. (2018) on diarrhea burden.
Core Methods
Subunit vaccines target adhesins; adjuvants boost responses; animal models assess challenge protection and IgG titers (Flores-Mireles et al., 2015; Terlizzi et al., 2017).
How PapersFlow Helps You Research Vaccine Development against Pathogenic Escherichia coli
Discover & Search
Research Agent uses searchPapers and exaSearch to find subunit vaccine studies, then citationGraph on Flores-Mireles et al. (2015) reveals 3932 citing papers on UPEC virulence for vaccine targets. findSimilarPapers expands to adjuvant strategies from Sarowska et al. (2019).
Analyze & Verify
Analysis Agent applies readPaperContent to extract immunogenicity data from Terlizzi et al. (2017), then runPythonAnalysis with pandas to quantify protection rates across animal models. verifyResponse (CoVe) and GRADE grading verify claims on adjuvant efficacy against E. coli pathotypes.
Synthesize & Write
Synthesis Agent detects gaps in coverage for enterohaemorrhagic strains (Frankel et al., 1998), flags contradictions in genomic diversity impacts (Touchon et al., 2009). Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to draft vaccine review manuscripts with exportMermaid for pathotype diagrams.
Use Cases
"Analyze protection rates from E. coli fimbriae vaccines in mouse UTI models"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Flores-Mireles 2015) → runPythonAnalysis (pandas meta-analysis of rates) → statistical output with p-values and GRADE scores.
"Draft LaTeX review on extraintestinal E. coli vaccine adjuvants"
Synthesis Agent → gap detection → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Sarowska 2019, Terlizzi 2017) → latexCompile → PDF with inline citations.
"Find code for E. coli virulence factor sequence analysis"
Research Agent → paperExtractUrls (Touchon 2009) → paperFindGithubRepo → githubRepoInspect → code for genomic diversity simulation downloaded.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ E. coli pathotype papers: searchPapers → citationGraph → structured report on vaccine gaps. DeepScan applies 7-step analysis with CoVe checkpoints to verify preclinical immunogenicity claims from Flores-Mireles et al. (2015). Theorizer generates hypotheses for multi-pathotype vaccines from virulence data in Frankel et al. (1998).
Frequently Asked Questions
What defines vaccine development against pathogenic E. coli?
It involves subunit vaccines targeting fimbriae, flagella, and autotransporters for diarrheagenic and extraintestinal strains, tested in preclinical models (Terlizzi et al., 2017).
What methods assess vaccine efficacy?
Immunogenicity measures antibody titers; protection tested via bacterial challenge in mice for UTI and diarrhea models (Flores-Mireles et al., 2015; Rahim et al., 2018).
What are key papers?
Flores-Mireles et al. (2015, 3932 citations) on UPEC mechanisms; Sarowska et al. (2019, 674 citations) on extraintestinal virulence; Frankel et al. (1998, 661 citations) on EPEC/EHEC.
What open problems exist?
No approved vaccines; antigenic diversity hinders broad protection (Touchon et al., 2009); human trial translation from models unachieved.
Research Escherichia coli research studies with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Vaccine Development against Pathogenic Escherichia coli with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the Escherichia coli research studies Research Guide